Your Web News in One Place

Help Webnuz

Referal links:

Sign up for GreenGeeks web hosting
January 16, 2018 12:00 am

FDA Approves First Drug Aimed at Women With Inherited Breast Cancer

U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. From a report: The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy. The drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA. Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. The company is offering patients financial assistance.

Read more of this story at Slashdot.


Original Link: http://rss.slashdot.org/~r/Slashdot/slashdot/~3/2ZiJ6PvqHxM/fda-approves-first-drug-aimed-at-women-with-inherited-breast-cancer

Share this article:    Share on Facebook
View Full Article

Slashdot

Slashdot was originally created in September of 1997 by Rob "CmdrTaco" Malda. Today it is owned by Geeknet, Inc..

More About this Source Visit Slashdot